EVMN Latest Press Releases

-- August 6, 2026 --

Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights Business Wire 4:05 PM

-- July 30, 2026 --

Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis Business Wire 8:00 AM

-- July 7, 2026 --

Evommune, Inc. (EVMN) Securities Fraud Investigation - Levi & Korsinsky PRNewswire 2:09 PM

-- June 30, 2026 --

Evommune, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Evommune, Inc. (EVMN) PRNewswire 1:39 PM

-- June 29, 2026 --

Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria Business Wire 8:30 AM

-- May 7, 2026 --

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights Business Wire 4:05 PM

-- April 6, 2026 --

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine Business Wire 9:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software